Overview
- Total revenue reached $15.2 billion in the third quarter, topping consensus estimates of $14.8 billion and marking the company’s largest quarter.
- Net profit rose 77 percent to $2.53 billion from a year earlier, driven by strong performance in oncology.
- Cancer treatments accounted for almost 44 percent of quarterly revenue, with oncology sales up about 16 percent.
- AstraZeneca reiterated its outlook, including guidance for high single-digit revenue growth and low double-digit core earnings per share growth in 2025.
- Investors approved a direct New York listing as the company advances a US pricing agreement that lowers drug costs in exchange for a three-year tariff delay, while retaining its UK headquarters and primary London listing.